TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent

American Journal of Hematology 2026 Open access

Read full text
Authors: Naseema Gangat, Momna Warraich, Sudhesh Kumar, Mahnoor Fatima, Kristen Beth McCullough, Kebede H. Begna, Aref Al‐Kali, Mrinal M. Patnaik, William J. Hogan, Abhishek Mangaonkar, Antoine N. Saliba, Mehrdad Hefazi Torghabeh
+8 more Hassan Alkhateeb, Mithun V. Shah, James M. Foran, Talha Badar, Jeanne M. Palmer, Cecilia Arana Yi, Animesh Pardanani, Ayalew Tefferi
DOI: 10.1002/ajh.70248
Cited by: 1
References: 18

Abstract

Survival outcome among 82 Mayo Clinic patients with blast/accelerated phase myeloproliferative neoplasm (MPN-BP/AP).

Fields of Study & Subjects

Myeloproliferative Neoplasms: Diagnosis and Treatment Chronic Myeloid Leukemia Treatments Acute Myeloid Leukemia Research

Publication details

Journal / source
American Journal of Hematology
Publisher
Wiley
Volume
101
Issue
4
Pages
866–871
Publication date
18 February 2026
Language
EN